Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-07-19
2011-07-19
Haddad, Maher M (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07981619
ABSTRACT:
The present invention provides a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease (COPD) comprising cytokeratin 18 protein as an active ingredient. The present invention also provides a diagnostic composition and a diagnostic kit for diagnosing COPD comprising cytokeratin 18 protein. The present invention further provides a composition for screening a therapeutic agent for COPD, comprising one or more of cytokeratin 18 protein or autoantibodies to cytokeratin 18 obtained from patients with COPD and a method for screening a therapeutic agent for COPD using this composition. The present invention still further provides methods for diagnosing, preventing or treating COPD using cytokeratin 18 protein.
REFERENCES:
patent: 2002/0122791 (2002-09-01), Nicolette
patent: 2008/0138913 (2008-06-01), Jeon et al.
patent: WO 03/023002 (2003-03-01), None
patent: WO 03/098211 (2003-11-01), None
patent: WO 2006/073254 (2006-07-01), None
Dobashi et al., Elevation of Anti-Cytokeratin 18 Antibody and Circulating Cytokeratin 18: Anti-Cytokeratin 18 Antibody Immune Complexes in Sera of Patients with Idiopathic Pulmonary Fibrosis. Lung, vol. 178, No. 3, 171-179, 2000.
Celli BR, et al., Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932-46.
Kuo et al. Identification and clinical association of anti-cytokeratin 18 autoantibody in COPD .Immunology Letters 128 (2010) 131-136.
GenBank Accession No. AAV38219, Oct 2004, N. Kalnine et al.
Nahm et al,American J. Respiratory Critical Care Medicine, 165 (11);1536-1539 (2002).
Kanazawa et al,Clinical Science, 94:531-535 (1998).
Veeramachaneni et al,Archives Pathology Laboratory Medicine, 125:1494-1495 (2001).
Ryu et al, “Obstructive Lung Diseases: COPD, Asthma, and Many Imitators,”Mayo Clinic Proceedings, vol. 76, No. 11, pp. 1144-1153, Nov. 2001.
Jeffery, “Remodeling and Inflammation of Bronchi in Asthma and Chronic Obstructive Pulmonary Disease,”Proceedings of the American Thoracic Society, vol. 1, No. 3, pp. 176-183, 2004.
Blast Comparison of human and bovine cytokeratin 18 from Corresponding European Application No. 06 715 883.7, pp. 1-3, Oct. 22, 2009.
Chanez P., “Severe asthma is an epithelial disease”, Eur Respir J, 2005, vol. 25 (6), p. 945-946.
Giallongo, Agata et al, “Molecular cloning and nucleotide sequence of a full-length cDNA for human α enolase”, Proc. Natl. Acad. Sci. USA, Biochemistry 1986, vol. 83 (18), p. 6741-6745.
Global Initiative for Asthma, “Global Strategy for Asthma Management and Prevention”, National Institutes of Health—National Heart, Lung and Blood Institute (NIH publication 02-3659), 2002, p. i-x, iii and 1-176.
Ishiguru et al, “Identification ofCandida albicansAntigens Reactive with Immunoglobulin E Antibody of Human Sera”, Infection and Immunity, 1992, vol. 60 (4), p. 1550-1557.
Lassalle, et al, “T and B cell immune response to a 55-kDA endothelial cell-derived antigen in severe asthma*”, European Journal Immunology, 1992, vol. 23 (4), p. 796-803.
Nahm et al, “Identification of α-enolase as an autoantigen associated with severe asthma”, Journal Allergy Clinical Immunology, 2006, vol. 118 (2), p. 376-381.
Nittner-Marszalska et al, “Skin prick test response to enzyme enolase of the baker's yeast (Saccharomyces cerevisiae) in diagnosis of respiratory allergy”, Clinical Research, Med Sci Monit, 2001, 7(1), p. 121-124.
Pancholi, “Multifunctional α-enolase: its role in diseases”, Cellular and Molecular Life Sciences, 2001, vol. 58 (7), p. 902-920.
Yavuz et al, “Comparative Analysis of Autoantibodies Against α-Fodrin in Serum, Tear Fluid, and Saliva from Patients with Sjögren's Syndrome”, The Journal of Rheumatology, 2006, vol. 33 (7), p. 1289-1292.
Wagner et al, “Autoimmune Mechanism in Diseases of the Respiratory Tract,”Acta Allergologica, vol. 20, pp. 1-9, 1965.
Moll et al, “The Catalog of Human Cytokeratins: Patterns of Expression in Normal Epithelia, Tumors and Cultured Cells,”Cell, vol. 31, pp. 11-24, Nov. 1982.
O'Byrne et al, “The Many Faces of Airway Inflammation,”American Journal of Respiratory and Critical Care Medicine, vol. 159, pp. S41-S66, 1999.
Saarloos et al, “Intermediate Filament, Laminin and Integrin Expression in Lacrimal Gland Acinar Cells: Comparison of an Immortalized Cell Line to Primary Cells, and Their Response to Retinoic Acid,”Current Eye Research, vol. 19, No. 5, pp. 439-449, 1999.
Pauwels et al, “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease,”American Journal of Respiratory and Critical Care Medicine, vol. 163, pp. 1256-1276, 2001.
Agusti et al, “Hypothesis: Does COPD have an Autoimmune Component?”Thorax, vol. 58, pp. 832-834, 2003.
Hodge et al, “Increased Airway Epithelial and T-Cell Apoptosis in COPD Remains Despite Smoking Cessation,”European Respiratory Journal, vol. 25, No. 3, pp. 447-454, 2005.
Taraseviciene-Stewart et al, “An Animal Model of Autoimmune Emphysema,”American Journal of Respiratory Critical Care Medicine, vol. 171, pp. 734-742, 2005.
Jeon Sook-yeong
Nahm Dong-ho
Haddad Maher M
Porter Wright Morris & Arthur
LandOfFree
Composition for prevention, treatment, and diagnosis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition for prevention, treatment, and diagnosis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for prevention, treatment, and diagnosis of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2711387